NeuBase Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Sep. 30, 2021

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of September 30,
	2021		2020
Accrued compensation and benefits	$	880,707	$	88,527
Accrued consulting settlement		200,000		—
Accrued professional fees		299,557		241,755
Accrued research and development		297,047		41,313
Accrued franchise tax		30,720		155,865
Accrued patent expenses		—		24,716
Other accrued expenses		39,715		3,707
Total	$	1,747,746	$	555,883